5 Steps
Maximum: 2 CME cr.
16 new discussion posts (16 published)
Sign in to view your progression
Program Overview
Learning Objectives
Target Audience
Credit Designation
Disclosure/Disclaimer

This course provides an overview on how to prevent and treat cancer-associated thrombosis.

Module 1: Primary Thromboprophylaxis in Ambulatory Patients with Cancer

  • To identify ambulant cancer patients risk for VTE
  • To identify patients who may benefit from primary prevention
  • To discuss type, dose and duration of anticoagulation for primary prevention of cancer-associated VTE

Module 2:  Treatment of Cancer-Associated Thrombosis

  • Describe the epidemiology and clinical relevance of venous thromboembolic (VTE) complications in cancer patients
  • Following this course, participants will be able to advise treatments the acute and long-term treatment of cancer-associated thrombosis (CAT)
  • Following this course, participants will strategize how to use DOACs for the management of cancer-associated thrombosis and the clinical characteristics to consider in tailoring anticoagulation management for the treatment of CAT

This cancer-associated thrombosis (CAT) education course is targeted at general hematologists and specifically physicians and other health care professionals who care for patients with cancer around the world.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

 

AMA Credit Designation Statement:

The Medical College of Wisconsin designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course was supported by an unrestricted educational grant from Bayer.

All persons in control of content have NO relevant financial relationships to disclose except:

Name:

Company:

Role:

Marc Carrier, MD

 Sanofi Aventis, Leo Pharma, Bayer, Aspen, Pfizer, Boehringer Ingelheim, Servier, Bristol-Myers Squibb (AVERT), Octapharma

Advisory Board member,

Speaker

 

Alok A. Khorana, MD

Janssen, Bayer, Pfizer

Consulting

Simon Noble, MD

Leo Pharma, Pfizer, Bayer, Daiichi Sankyo

Speaker, Consulting

Tzu-Fei Wang, MD

Pfizer

Advisory Board

In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships.  These relationships were reviewed via the MCW conflict of interest resolution process and resolved.  

Personal Information form - mandatory to receive CME
Please login here or create an account to view this content.
Pre-Test
Module1 : Primary Thromboprophylaxis in Ambulatory Patients with Cancer
Module 2: Treatment of Cancer-Associated Thrombosis
Post-Test, Evaluation & Certificate

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies